U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA)...

Related Keywords

Japan ,United States ,Australia ,Canada ,Tokyo ,Shitara ,Aichi ,United Kingdom ,American ,America ,Moitreyee Chatterjee Kishore ,Naoki Okamura ,Rare Diseases Information Center ,Translational Sciences ,American Cancer Society ,Japan Ministry Of Health ,National Institutes Of Health Center ,Prnewswire Astellas Pharma Inc ,National Cancer Institute ,American Society Of Clinical Oncology ,End Results Program ,Drug Administration ,Oncology Development ,Astellas Pharma Inc ,Biologics License Application ,Prescription Drug User Fee Act ,Senior Vice President ,Immuno Oncology Development ,Locally Advanced Unresectable Metastatic Gastric ,Gastroesophageal Junction ,South America ,Clinical Oncology ,Cancers Symposium ,Nature Medicine ,Focus Immuno Oncology ,Focus Area Approach ,End Results ,Gastric Cancer ,Health National Center ,Advancing Translational ,Rare Diseases Information ,